Publications by authors named "Irene Bailey"

Claim this Profile
P
Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial.
Jean Y Tang, M Peter Marinkovich, Karen Wiss, Daniel McCarthy, Amanda Truesdale, Irene Bailey

Lancet· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of antipruritic effects of serlopitant, a neurokinin 1 receptor antagonist, in patients with epidermolysis bullosa: A phase 2 randomized controlled trial.
Utako Okata-Karigane, Pirunthan Pathmarajah, Emily S Gorell, Katie Sum, Kiana Yekrang, Irene Bailey

J Eur Acad Dermatol Venereol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A scalable, GMP-compatible, autologous organotypic cell therapy for Dystrophic Epidermolysis Bullosa.
Gernot Neumayer, Jessica L Torkelson, Shengdi Li, Kelly McCarthy, Hanson H Zhen, Irene Bailey

bioRxiv· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa.
Jodi Y So, Jaron Nazaroff, Chinonso V Iwummadu, Nicki Harris, Emily S Gorell, Irene Bailey

Orphanet J Rare Dis· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of Cutaneous Squamous Cell Carcinoma With the Topical Histone Deacetylase Inhibitor Remetinostat.
James M Kilgour, Aatman Shah, Shaundra Eichstadt, Irene Bailey, Sumaira Z Aasi

JAMA Dermatol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Open-Label, Single-Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel in Patients with Basal Cell Carcinoma.
James M Kilgour, Aatman Shah, Nicole M Urman, Shaundra Eichstadt, Hanh N Do, Irene Bailey

Clin Cancer Res· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequent basal cell cancer development is a clinical marker for inherited cancer susceptibility.
Hyunje G Cho, Karen Y Kuo, Shufeng Li, Irene Bailey, Sumaira Aasi

JCI Insight· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis